HK Stock MarketDetailed Quotes

PHARMARON (03759)

Watchlist
  • 15.520
  • +0.590+3.95%
15min DelayNot Open Jun 12 16:07 CST
28.40BMarket Cap14.81P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

PHARMARON (03759) Income Statement

All
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q9)Sep 30, 2025
(Q6)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
Turnover
15.48%3.58B
14.82%14.1B
14.38%10.09B
14.93%6.44B
16.03%3.1B
6.39%12.28B
3.00%8.82B
-0.63%5.6B
-1.95%2.67B
12.39%11.54B
Operating income
15.48%3.58B
14.82%14.1B
14.38%10.09B
14.93%6.44B
16.03%3.1B
6.39%12.28B
3.00%8.82B
-0.63%5.6B
-1.95%2.67B
12.39%11.54B
Cost of sales
----
-13.67%-9.24B
----
-13.64%-4.27B
----
-9.18%-8.13B
----
-4.27%-3.76B
----
-14.21%-7.44B
Operating expenses
-17.50%-2.42B
-13.67%-9.24B
-13.77%-6.63B
-13.64%-4.27B
-14.31%-2.06B
-9.18%-8.13B
-6.36%-5.83B
-4.27%-3.76B
-2.84%-1.8B
-14.21%-7.44B
Gross profit
11.50%1.16B
17.07%4.86B
15.58%3.45B
17.54%2.17B
19.58%1.04B
1.33%4.15B
-2.97%2.99B
-9.30%1.85B
-10.55%872.15M
9.22%4.09B
Selling expenses
-13.40%-78.07M
-18.58%-306.46M
-18.23%-220.57M
-16.26%-142.94M
-24.12%-68.85M
-2.24%-258.43M
3.80%-186.56M
3.02%-122.95M
0.41%-55.47M
-9.87%-252.78M
Administrative expenses
-11.36%-442.04M
-11.48%-1.85B
-5.15%-1.27B
-0.91%-848.84M
0.42%-396.94M
0.50%-1.66B
0.62%-1.21B
0.50%-841.22M
3.81%-398.61M
-7.75%-1.67B
Research and development expenses
-14.37%-139.77M
-22.75%-576.02M
-17.86%-391.6M
-20.53%-250.46M
-30.56%-122.21M
-4.68%-469.26M
-11.96%-332.25M
-14.06%-207.8M
-21.82%-93.61M
-58.78%-448.28M
Profit from asset sales
461.47%1.12M
----
84.49%-3.71M
----
98.45%-310.59K
----
-9,732.09%-23.92M
----
-17,640.70%-20M
----
Revaluation surplus
36.08%-8.18M
----
408.88%68.33M
----
-1,035.82%-12.8M
----
-155.03%-22.12M
----
-103.94%-1.13M
----
-Changes in the fair value of other assets
36.08%-8.18M
----
408.88%68.33M
----
-1,035.82%-12.8M
----
-155.03%-22.12M
----
-103.94%-1.13M
----
Impairment and provision
33.79%-4.85M
31.08%-80.28M
-61.79%-48.02M
-61.91%-37.14M
-13.26%-7.33M
-225.15%-116.49M
-25.70%-29.68M
-114.13%-22.94M
-48.33%-6.47M
-69.33%-35.83M
-Goodwill impairment
----
----
----
----
----
---73.54M
----
----
----
----
-Other impairment is provision
33.79%-4.85M
-86.93%-80.28M
-61.79%-48.02M
-61.91%-37.14M
-13.26%-7.33M
-19.88%-42.95M
-25.70%-29.68M
-114.13%-22.94M
-48.33%-6.47M
-69.33%-35.83M
Special items of operating profit
5,690.74%43.95M
-75.38%201.06M
-96.88%20.55M
-93.70%46.77M
-101.22%-786.05K
143.01%816.76M
521.30%659.56M
549.74%742.27M
81.86%64.63M
65.17%336.11M
Operating profit
23.09%505.24M
-8.83%2.24B
-14.96%1.5B
-32.67%939.58M
23.68%410.45M
21.56%2.46B
22.45%1.76B
41.44%1.4B
-29.53%331.85M
8.28%2.02B
Financing income
100.94%13.51M
----
-54.23%29.92M
----
-72.35%6.73M
----
204.81%65.38M
----
272.73%24.33M
----
Financing cost
-17.52%-51.56M
20.89%-192.81M
26.76%-141.66M
31.89%-94.17M
37.82%-43.88M
-33.77%-243.72M
-44.25%-193.42M
-55.29%-138.25M
-50.77%-70.57M
-8.89%-182.19M
Share of profits of associates
----
-10.02%-135.61M
----
-7.76%-32.66M
----
-5,814.40%-123.26M
----
-375.96%-30.31M
----
93.84%-2.08M
Special items of earning before tax
-1,910.53%-5.75M
----
-170.25%-14.49M
----
-240.00%-286.04K
----
28.90%-5.36M
----
104.11%204.32K
----
Earning before tax
13.52%412.76M
-8.54%1.91B
-18.06%1.33B
-33.75%812.76M
35.35%363.59M
13.79%2.09B
22.78%1.62B
35.04%1.23B
-37.03%268.62M
10.29%1.84B
Tax
----
5.19%-357.52M
----
-11.27%-160.13M
----
-47.25%-377.1M
----
-15.63%-143.91M
----
18.50%-256.11M
After-tax profit from continuing operations
11.00%310.41M
-9.27%1.56B
-22.15%1.07B
-39.74%652.63M
29.52%279.65M
8.37%1.71B
20.69%1.37B
38.12%1.08B
-38.33%215.92M
16.98%1.58B
Earning after tax
11.00%310.41M
-9.27%1.56B
-22.15%1.07B
-39.74%652.63M
29.52%279.65M
8.37%1.71B
20.69%1.37B
38.12%1.08B
-38.33%215.92M
16.98%1.58B
Minority profit
3.75%-24.95M
-37.28%-108.71M
-42.68%-75.04M
-60.11%-48.77M
-77.08%-25.92M
-310.00%-79.19M
-1,064.87%-52.59M
-1,404.05%-30.46M
-873.86%-14.64M
14.03%-19.32M
Profit attributable to shareholders
9.75%335.36M
-7.22%1.66B
-19.76%1.14B
-37.00%701.4M
32.54%305.58M
12.01%1.79B
24.82%1.42B
41.64%1.11B
-33.80%230.56M
16.48%1.6B
Basic earnings per share
7.14%0.186
-6.81%0.9443
-19.32%0.6477
-36.58%0.3984
33.54%0.1736
12.18%1.0133
24.85%0.8028
41.42%0.6282
-33.94%0.13
16.55%0.9033
Diluted earnings per share
6.75%0.185
-7.12%0.9393
-19.35%0.6467
-36.57%0.3978
33.51%0.1733
12.13%1.0113
24.89%0.8019
41.37%0.6271
-34.01%0.1298
16.54%0.9019
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
IAS
CAS (2007)
IAS
CAS (2007)
IAS
CAS (2007)
IAS
CAS (2007)
IAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
Ernst & Young Huaming Accounting Firm (Special General Partnership)
--
--
--
Ernst & Young Huaming Accounting Firm (Special General Partnership)
--
--
--
Ernst & Young
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q9)Sep 30, 2025(Q6)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023
Turnover 15.48%3.58B14.82%14.1B14.38%10.09B14.93%6.44B16.03%3.1B6.39%12.28B3.00%8.82B-0.63%5.6B-1.95%2.67B12.39%11.54B
Operating income 15.48%3.58B14.82%14.1B14.38%10.09B14.93%6.44B16.03%3.1B6.39%12.28B3.00%8.82B-0.63%5.6B-1.95%2.67B12.39%11.54B
Cost of sales -----13.67%-9.24B-----13.64%-4.27B-----9.18%-8.13B-----4.27%-3.76B-----14.21%-7.44B
Operating expenses -17.50%-2.42B-13.67%-9.24B-13.77%-6.63B-13.64%-4.27B-14.31%-2.06B-9.18%-8.13B-6.36%-5.83B-4.27%-3.76B-2.84%-1.8B-14.21%-7.44B
Gross profit 11.50%1.16B17.07%4.86B15.58%3.45B17.54%2.17B19.58%1.04B1.33%4.15B-2.97%2.99B-9.30%1.85B-10.55%872.15M9.22%4.09B
Selling expenses -13.40%-78.07M-18.58%-306.46M-18.23%-220.57M-16.26%-142.94M-24.12%-68.85M-2.24%-258.43M3.80%-186.56M3.02%-122.95M0.41%-55.47M-9.87%-252.78M
Administrative expenses -11.36%-442.04M-11.48%-1.85B-5.15%-1.27B-0.91%-848.84M0.42%-396.94M0.50%-1.66B0.62%-1.21B0.50%-841.22M3.81%-398.61M-7.75%-1.67B
Research and development expenses -14.37%-139.77M-22.75%-576.02M-17.86%-391.6M-20.53%-250.46M-30.56%-122.21M-4.68%-469.26M-11.96%-332.25M-14.06%-207.8M-21.82%-93.61M-58.78%-448.28M
Profit from asset sales 461.47%1.12M----84.49%-3.71M----98.45%-310.59K-----9,732.09%-23.92M-----17,640.70%-20M----
Revaluation surplus 36.08%-8.18M----408.88%68.33M-----1,035.82%-12.8M-----155.03%-22.12M-----103.94%-1.13M----
-Changes in the fair value of other assets 36.08%-8.18M----408.88%68.33M-----1,035.82%-12.8M-----155.03%-22.12M-----103.94%-1.13M----
Impairment and provision 33.79%-4.85M31.08%-80.28M-61.79%-48.02M-61.91%-37.14M-13.26%-7.33M-225.15%-116.49M-25.70%-29.68M-114.13%-22.94M-48.33%-6.47M-69.33%-35.83M
-Goodwill impairment -----------------------73.54M----------------
-Other impairment is provision 33.79%-4.85M-86.93%-80.28M-61.79%-48.02M-61.91%-37.14M-13.26%-7.33M-19.88%-42.95M-25.70%-29.68M-114.13%-22.94M-48.33%-6.47M-69.33%-35.83M
Special items of operating profit 5,690.74%43.95M-75.38%201.06M-96.88%20.55M-93.70%46.77M-101.22%-786.05K143.01%816.76M521.30%659.56M549.74%742.27M81.86%64.63M65.17%336.11M
Operating profit 23.09%505.24M-8.83%2.24B-14.96%1.5B-32.67%939.58M23.68%410.45M21.56%2.46B22.45%1.76B41.44%1.4B-29.53%331.85M8.28%2.02B
Financing income 100.94%13.51M-----54.23%29.92M-----72.35%6.73M----204.81%65.38M----272.73%24.33M----
Financing cost -17.52%-51.56M20.89%-192.81M26.76%-141.66M31.89%-94.17M37.82%-43.88M-33.77%-243.72M-44.25%-193.42M-55.29%-138.25M-50.77%-70.57M-8.89%-182.19M
Share of profits of associates -----10.02%-135.61M-----7.76%-32.66M-----5,814.40%-123.26M-----375.96%-30.31M----93.84%-2.08M
Special items of earning before tax -1,910.53%-5.75M-----170.25%-14.49M-----240.00%-286.04K----28.90%-5.36M----104.11%204.32K----
Earning before tax 13.52%412.76M-8.54%1.91B-18.06%1.33B-33.75%812.76M35.35%363.59M13.79%2.09B22.78%1.62B35.04%1.23B-37.03%268.62M10.29%1.84B
Tax ----5.19%-357.52M-----11.27%-160.13M-----47.25%-377.1M-----15.63%-143.91M----18.50%-256.11M
After-tax profit from continuing operations 11.00%310.41M-9.27%1.56B-22.15%1.07B-39.74%652.63M29.52%279.65M8.37%1.71B20.69%1.37B38.12%1.08B-38.33%215.92M16.98%1.58B
Earning after tax 11.00%310.41M-9.27%1.56B-22.15%1.07B-39.74%652.63M29.52%279.65M8.37%1.71B20.69%1.37B38.12%1.08B-38.33%215.92M16.98%1.58B
Minority profit 3.75%-24.95M-37.28%-108.71M-42.68%-75.04M-60.11%-48.77M-77.08%-25.92M-310.00%-79.19M-1,064.87%-52.59M-1,404.05%-30.46M-873.86%-14.64M14.03%-19.32M
Profit attributable to shareholders 9.75%335.36M-7.22%1.66B-19.76%1.14B-37.00%701.4M32.54%305.58M12.01%1.79B24.82%1.42B41.64%1.11B-33.80%230.56M16.48%1.6B
Basic earnings per share 7.14%0.186-6.81%0.9443-19.32%0.6477-36.58%0.398433.54%0.173612.18%1.013324.85%0.802841.42%0.6282-33.94%0.1316.55%0.9033
Diluted earnings per share 6.75%0.185-7.12%0.9393-19.35%0.6467-36.57%0.397833.51%0.173312.13%1.011324.89%0.801941.37%0.6271-34.01%0.129816.54%0.9019
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)IASCAS (2007)IASCAS (2007)IASCAS (2007)IASCAS (2007)IAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --Ernst & Young Huaming Accounting Firm (Special General Partnership)------Ernst & Young Huaming Accounting Firm (Special General Partnership)------Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 0.00%
Sample Name
Sample Code
 -3.45%
Sample Name
Sample Code
 -4.98%
4
PETROCHINA
00857
-5.22%
5
KUNLUN ENERGY
00135
-5.91%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +11.90%
Sample Name
Sample Code
 +0.43%
Sample Name
Sample Code
 -0.54%
4
Emdoor Information
001314
-6.88%
5
Rockchip Electronics
603893
-7.20%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -